Immunosuppression and plasma-exchange in the treatment of Goodpasture's syndrome - PubMed (original) (raw)
Immunosuppression and plasma-exchange in the treatment of Goodpasture's syndrome
C M Lockwood et al. Lancet. 1976.
Abstract
Seven patients with Goodpasture's syndrome induced by anti-glomerular-basement-membrane (anti-G.B.M.) antibody were treated by a regimen of intensive plasma-exchange, cytotoxic drugs, and steroids. In the three patients retaining some renal function at presentation, this regimen led to suppression and eventual termination of antibody synthesis with improvement in renal function. In four patients, all anuric at presentation, antibody to G.B.M. persisted with variable reduction in the circulating levels. No return of renal function occurred in this group, all of whom had extensive changes on renal biopsy. Pulmonary haemorrhage, life-threatening in one patient, was rapidly controlled in all five patients in whom it was a presenting feature. In addition to its effect on antibody levels, plasma-exchange, using volume-replacement with plasma-protein fraction (P.P.F.), resulted in substantial depletion of complement and fibrinogen, mediators possibly contributing to the antibody-induced injury.
Similar articles
- Failure of plasma exchange and immunosuppression to improve renal function in Goodpasture's syndrome.
McLeish KR, Maxwell DR, Luft FC. McLeish KR, et al. Clin Nephrol. 1978 Aug;10(2):71-3. Clin Nephrol. 1978. PMID: 699402 - Recovery from Goodpasture's syndrome after immunosuppressive treatment and plasmapheresis.
Lockwood CM, Boulton-Jones JM, Lowenthal RM, Simpson IJ, Peters DK. Lockwood CM, et al. Br Med J. 1975 May 3;2(5965):252-4. doi: 10.1136/bmj.2.5965.252. Br Med J. 1975. PMID: 1131574 Free PMC article. - Cutting edge issues in Goodpasture's disease.
Chan AL, Louie S, Leslie KO, Juarez MM, Albertson TE. Chan AL, et al. Clin Rev Allergy Immunol. 2011 Oct;41(2):151-62. doi: 10.1007/s12016-010-8222-2. Clin Rev Allergy Immunol. 2011. PMID: 21207195 Review. - Goodpasture's syndrome: recurrence after a five-year remission. Case report and review of the literature.
Klasa RJ, Abboud RT, Ballon HS, Grossman L. Klasa RJ, et al. Am J Med. 1988 Apr;84(4):751-5. doi: 10.1016/0002-9343(88)90114-3. Am J Med. 1988. PMID: 3041810 Review.
Cited by
- Unleashing the power of complement activation: unraveling renal damage in human anti-glomerular basement membrane disease.
Tang A, Zhao X, Tao T, Xie D, Xu B, Huang Y, Li M. Tang A, et al. Front Immunol. 2023 Sep 15;14:1229806. doi: 10.3389/fimmu.2023.1229806. eCollection 2023. Front Immunol. 2023. PMID: 37781380 Free PMC article. Review. - Using imlifidase to elucidate the characteristics and importance of anti-GBM antibodies produced after start of treatment.
Tyrberg L, Andersson F, Uhlin F, Hellmark T, Segelmark M. Tyrberg L, et al. Nephrol Dial Transplant. 2023 Dec 20;39(1):45-54. doi: 10.1093/ndt/gfad132. Nephrol Dial Transplant. 2023. PMID: 37385828 Free PMC article. - Relationship between anti-GBM antibodies and kidney outcomes in patients with anti-GBM disease.
Zhu M, Wang J, Le W, Xu F, Jin Y, Jiao C, Zhang H. Zhu M, et al. J Nephrol. 2023 Apr;36(3):789-797. doi: 10.1007/s40620-022-01508-5. Epub 2022 Nov 24. J Nephrol. 2023. PMID: 36427163 - Anti-glomerular Basement Membrane Glomerulonephritis: A Study in Real Life.
Sánchez-Agesta M, Rabasco C, Soler MJ, Shabaka A, Canllavi E, Fernández SJ, Cazorla JM, López-Rubio E, Romera A, Barroso S, Huerta A, Calle L, Sierra M, Domínguez-Torres P, Moreno-Ramírez M, Afonso S, Mascarós V, Coca A, Espinosa M; Spanish Group for the Study of Glomerular Diseases (GLOSEN). Sánchez-Agesta M, et al. Front Med (Lausanne). 2022 Jul 5;9:889185. doi: 10.3389/fmed.2022.889185. eCollection 2022. Front Med (Lausanne). 2022. PMID: 35865174 Free PMC article. - An update on lipid apheresis for familial hypercholesterolemia.
Taylan C, Weber LT. Taylan C, et al. Pediatr Nephrol. 2023 Feb;38(2):371-382. doi: 10.1007/s00467-022-05541-1. Epub 2022 Apr 25. Pediatr Nephrol. 2023. PMID: 35467154 Free PMC article. Review.